Areas of Research

WHAT RESEARCH ARE WE SUPPORTING?

 

We are currently focused on three areas of biotherapeutics research — oncolytic viruses, adoptive cell therapy and therapeutic antibodies — and have a fourth field of research that assesses the societal value and economic viability of new therapies in development. All of these research fields are supported by core facilities critical infrastructure required to move these technologies forward.
 
However, we strongly encourage projects that involve more than one of these areas of research.

ONCOLYTIC VIRUSES

 
rhabdovirus1500 This new and highly innovative approach to cancer treatment uses cancer-killing viruses to target, infect and kill tumour cells. At the same time, these viruses train our immune system to identify cancer cells, which can provide lasting anti-tumour responses so the cancer doesn’t spread and recur. The first virus therapy, T-VEC (Amgen), obtained U.S. FDA approval in October 2015. Others, such as Pexa-Vec (SillaJen), are already in mid-to-late stage clinical trials and showing promising results in patients with solid tumours.

ADOPTIVE CELL THERAPY

 
cell1500Immune cell therapy involves engineering or isolating cancer-fighting immune cells from a patient’s tumour, growing large numbers of these cells in the laboratory and then infusing them back into patients. Immune cells are naturally present in most tumours, but usually lack the strength or numbers to eradicate the cancer on their own. The immune cells can also be genetically or biologically manipulated to become more powerful. This approach has led to some unprecedented clinical responses in patients with advanced cancers.

THERAPEUTIC ANTIBODIES

 
antibodyisolated1500Natural antibodies are small proteins that the body produces to flag viruses, bacteria and cancer cells for destruction by the immune system. BioCanRx scientists are developing synthetic antibodies armed with potent toxins that can kill cancer cells directly, as well as antibodies directed against key immune regulatory checkpoints to drive the patient’s immune response towards heightened anti-cancer activity. These kinds of antibodies have already shown great promise in the clinic, and are without doubt the most successful anti-cancer biotherapeutics to date.